[1] |
Magliano DJ, Boyko EJ, IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS. 10th edition. Brussels: International Diabetes Federation, 2021.
|
[2] |
World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization, 2022.
|
[3] |
Pan SC, Ku CC, Kao D, et al. Effect of diabetes on tuberculosis control in 13 countries with high tuberculosis: a modelling study. Lancet Diabetes Endocrinol, 2015, 3(5):323-330. doi:10.1016/S2213-8587(15)00042-X.
|
[4] |
Lu P, Zhang Y, Liu Q, et al. Association of BMI, diabetes, and risk of tuberculosis: a population-based prospective cohort. Int J Infect Dis, 2021, 109:168-173. doi:10.1016/j.ijid.2021.06.053.
pmid: 34217872
|
[5] |
Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health, 2019, 7(4):e448 -e460. doi:10.1016/S2214-109X(18)30487-X.
|
[6] |
Li L, Lin Y, Mi F, et al. Screening of patients with tuberculosis for diabetes mellitus in China. Trop Med Int Health, 2012, 17(10):1294-1301. doi:10.1111/j.1365-3156.2012.03068.x.
pmid: 22830945
|
[7] |
Magee MJ, Kempker RR, Kipiani M, et al. Diabetes mellitus is associated with cavities, smear grade, and multidrug-resistant tuberculosis in Georgia. Int J Tuberc Lung Dis, 2015, 19(6):685-692. doi:10.5588/ijtld.14.0811.
pmid: 25946360
|
[8] |
Tegegne BS, Mengesha MM, Teferra AA, et al. Association between diabetes mellitus and multi-drug-resistant tuberculosis: evidence from a systematic review and meta-analysis. Syst Rev, 2018, 7(1):161. doi:10.1186/s13643-018-0828-0.
pmid: 30322409
|
[9] |
Nguyen CH, Pascopella L, Barry PM. Association between diabetes mellitus and mortality among patients with tuberculosis in California, 2010—2014. Int J Tuberc Lung Dis, 2018, 22(11):1269-1276. doi:10.5588/ijtld.18.0011.
|
[10] |
邓国防. 结核病与糖尿病共病的治疗管理专家共识. 中国防痨杂志, 2021, 43(1):12-22. doi:10.3969/j.issn.1000-6621.2021.01.004.
|
[11] |
中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断. 2017-11-09.
|
[12] |
李成, 周健. 2019年ADA糖尿病医学诊疗标准解读. 中国医学前沿杂志(电子版), 2019, 11(1):66-74. doi:10.12037/YXQY.2019.01-08.
|
[13] |
赵雁林, 王黎霞, 成诗明, 等. 分枝杆菌分离培养标准化操作程序及质量保证手册. 北京: 人民卫生出版社, 2013.
|
[14] |
赵雁林, 逄宇. 结核病实验室检验规程. 北京: 人民卫生出版社, 2015.
|
[15] |
World Health Organization. WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. Geneva: World Health Organization, 2018.
|
[16] |
Bagcchi S. WHO’s Global Tuberculosis Report 2022. Lancet Microbe, 2023, 4(1):e20. doi:10.1016/S2666-5247(22)00359-7.
|
[17] |
Rifat M, Milton AH, Hall J, et al. Development of multidrug resistant tuberculosis in Bangladesh: a case-control study on risk factors. PLoS One, 2014, 9(8):e105214. doi:10.1371/journal.pone.0105214.
|
[18] |
Song WM, Li YF, Liu JY, et al. Drug resistance of previously treated tuberculosis patients with diabetes mellitus in Shandong, China. Respir Med, 2020, 163:105897. doi:10.1016/j.rmed.2020.105897.
|
[19] |
Odone A, Houben RM, White RG, et al. The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets. Lancet Diabetes Endocrinol, 2014, 2(9):754-764. doi:10.1016/S2213-8587(14)70164-0.
|
[20] |
Ruesen C, Chaidir L, Ugarte-Gil C, et al. Diabetes is associa-ted with genotypically drug-resistant tuberculosis. Eur Respir J, 2020, 55(3):1901891. doi:10.1183/13993003.01891-2019.
|
[21] |
宋克玉, 张琴, 王雯菁, 等. 2017—2019年南京市1719株分枝杆菌耐药情况分析. 中国防痨杂志, 2020, 42(11):1214-1220. doi:10.3969/j.issn.1000-6621.2020.11.013.
|
[22] |
郭晶, 林霏申, 张向荣, 等. 南京地区2013—2014年结核分枝杆菌耐药流行情况调查. 临床肺科杂志, 2016, 21(6):1076-1079. doi:10.39669/j.issn.1009-6663.2016.06.032.
|
[23] |
Li M, Chen T, Hua Z, et al. Global, regional, and national prevalence of diabetes mellitus in patients with pulmonary tuberculosis: a systematic review and meta-analysis. Diabetol Metab Syndr, 2021, 13(1):127. doi:10.1186/s13098-021-00743-3.
pmid: 34717728
|
[24] |
Pan Y, Yu Y, Yi Y, et al. The differences in drug resistance between drug-resistant tuberculosis patients with and without diabetes mellitus in northeast China: a retrospective study. BMC Infect Dis, 2023, 23(1):162. doi:10.1186/s12879-023-08130-1.
pmid: 36922787
|
[25] |
Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocr Rev, 2016, 37(3):278-316. doi:10.1210/er.2015-1137.
pmid: 27159875
|
[26] |
Badgeba A, Shimbre MS, Gebremichael MA, et al. Determinants of Multidrug-Resistant Mycobacterium tuberculosis Infection: A Multicenter Study from Southern Ethiopia. Infect Drug Resist, 2022, 15:3523-3535. doi:10.2147/IDR.S363628.
|
[27] |
Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med, 2011, 9:81. doi:10.1186/1741-7015-9-81.
pmid: 21722362
|
[28] |
Song WM, Shao Y, Liu JY, et al. Primary drug resistance among tuberculosis patients with diabetes mellitus: a retrospective study among 7223 cases in China. Infect Drug Resist, 2019, 12:2397-2407. doi:10.2147/IDR.S217044.
|
[29] |
Hsu AH, Lee JJ, Chiang CY, et al. Diabetes is associated with drug-resistant tuberculosis in Eastern Taiwan. Int J Tuberc Lung Dis, 2013, 17(3):354-356. doi:10.5588/ijtld.11.0670.
pmid: 23228433
|
[30] |
El-Sheikh SMA, Metwally AS, Galal AAA. Impact of diabetes mellitus on rifampicin’s plasma concentration and bioavailability in patients with tuberculosis: A systematic review and meta-analysis study. Therapie, 2023, 78(3):313-324. doi:10.1016/j.therap.2022.05.005.
|
[31] |
Kumar AK, Chandrasekaran V, Kannan T, et al. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus. Eur J Clin Pharmacol, 2017, 73(1):65-70. doi:10.1007/s00228-016-2132-z.
pmid: 27651240
|
[32] |
Dheda K, Gumbo T, Maartens G, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med, 2017: S2213- 2600(17)30079-6. doi:10.1016/S2213-2600(17)30079-6.
|
[33] |
Long R, Chong H, Hoeppner V, et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis, 2009, 48(10):1354-1360. doi:10.1086/598196.
pmid: 19348594
|
[34] |
Li S, Liang Y, Hu X. Risk factors for multidrug resistance in tuberculosis patients with diabetes mellitus. BMC Infect Dis, 2022, 22(1):835. doi:10.1186/s12879-022-07831-3.
pmid: 36369020
|
[35] |
Huang D, Wang Y, Wang Y, et al. The impact of diabetes mellitus on drug resistance in patients with newly diagnosed tuberculosis: a systematic review and meta-analysis. Ann Palliat Med, 2020, 9(2):152-162. doi:10.21037/apm.2020.02.16.
pmid: 32268768
|
[36] |
Dean AS, Zignol M, Cabibbe AM, et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. PLoS Med, 2020, 17(1):e1003008. doi:10.1371/journal.pmed.1003008.
|
[37] |
Li Y, Shi J, Song W, et al. A retrospective cohort study on the treatment outcomes and genotyping of isoniazid-resistant tuberculosis patients in Eastern China. J Glob Antimicrob Resist, 2022, 30:335-339. doi:10.1016/j.jgar.2022.07.003.
pmid: 35817264
|
[38] |
Bermudez-Hernández GA, Pérez-Martínez DE, Madrazo-Moya CF, et al. Whole genome sequencing analysis to evaluate the influence of T2DM on polymorphisms associated with drug resistance in M.tuberculosis. BMC Genomics, 2022, 23(1):465. doi:10.1186/s12864-022-08709-z.
pmid: 35751020
|
[39] |
翁建平, 朱大龙, 母义明, 等. 糖尿病的未来:精准预测,精准诊断,精准治疗. 中华糖尿病杂志, 2019, 11(6):369-373. doi:10.3760/cma.j.issn.1674-5809.2019.06.001.
|